Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 12/20 | 0.45 |
| ▸ | CHRNA3 | P32297 | 12/20 | 0.45 |
| ▸ | CHRNA4 | P43681 | 12/20 | 0.45 |
| ▸ | CHRNB4 | P30926 | 11/20 | 0.45 |
| ▸ | CHRNA7 | P36544 | 9/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | GRM5 | P41594 | 1/20 | 0.35 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.32 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL742194 | 1.00 | CHRNB2 (0.45) | CHRNB2CHRNA3CHRNA4CHRNB4CHRNA7 | |
| SCHEMBL21593659 | 0.86 | CHRNB2 (0.47) | CHRNB2CHRNA3CHRNA4CHRNB4CHRNA7 | |
| SCHEMBL14110948 | 0.82 | SMN1; SMN2 (0.53) | CHRNB2CHRNA3CHRNA4CHRNB4SMN1; SMN2 | |
| SCHEMBL3174694 | 0.78 | CHRNB2 (0.34) | CHRNB2CHRNA3CHRNA4CHRNB4CHRNA7 | |
| SCHEMBL21808534 | 0.78 | CHRNB2 (0.34) | CHRNB2CHRNA3CHRNA4CHRNB4CHRNA7 | |
| SCHEMBL1404442 | 0.78 | CHRNB2 (0.34) | CHRNB2CHRNA3CHRNA4CHRNB4CHRNA7 | |
| SCHEMBL14804550 | 0.77 | GRM5 (0.38) | CHRNB2CHRNA3CHRNA4CHRNB4CHRNA7 | |
| Hydrochloric Acid SCHEMBL6336086 | 0.76 | CHRNB2 (0.33) | CHRNB2CHRNA3CHRNA4CHRNB4CHRNA7 | |
| SCHEMBL31510752 | 0.76 | KDM4E (0.34) | CHRNB2CHRNA3CHRNA4CHRNB4CHRNA7 | |
| SCHEMBL1008154 | 0.76 | KDM4E (0.34) | CHRNB2CHRNA3CHRNA4CHRNB4CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220106329-A1 | BICYCLIC ROR-GAMMA MODULATORS | ESCALIER BIOSCIENCES B V (US) | 2022-04-07 | — | — | US | disclosed |
| EP-3965766-A1 | COMBINATION OF AN ?2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONISTS WITH A TASK1/3 CHANNEL BLOCKER FOR THE TREATMENT OF SLEEP APNEA | Bayer Aktiengesellschaft (DE) | 2022-03-16 | — | — | EP | disclosed |
| US-11230555-B2 | Bicyclic RORγ modulators | ESCALIER BIOSCIENCES B.V. (US) | 2022-01-25 | — | — | US | disclosed |
| US-20210053987-A1 | BICYCLIC ROR-GAMMA MODULATORS | ESCALIER BIOSCIENCES B.V. | 2021-02-25 | — | — | US | disclosed |
| US-10300058-B2 | Tyrosine kinase inhibitor and uses thereof | Xuanzhu Pharma Co., Ltd. (CN) | 2019-05-28 | — | — | US | disclosed |
| US-10300058-B2 | Tyrosine kinase inhibitor and uses thereof | Xuanzhu Pharma Co., Ltd. (CN) | 2019-05-28 | — | — | US | disclosed |
| US-20170112833-A1 | Tyrosine Kinase Inhibitor And Uses Thereof | Xuanzhu Pharma Co., Ltd. (CN) | 2017-04-27 | — | — | US | disclosed |
| US-20170112833-A1 | Tyrosine Kinase Inhibitor And Uses Thereof | Xuanzhu Pharma Co., Ltd. (CN) | 2017-04-27 | — | — | US | disclosed |
| US-20170112833-A1 | Tyrosine Kinase Inhibitor And Uses Thereof | Xuanzhu Pharma Co., Ltd. (CN) | 2017-04-27 | — | — | US | disclosed |
| US-9309252-B2 | Pyrrolopyrimidine compounds as inhibitors of CDK4/6 | NOVARTIS AG (CH) | 2016-04-12 | — | — | US | disclosed |
| US-20130150342-A1 | PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF CDK4/6 | NOVARTIS AG (CH) | 2013-06-13 | — | — | US | disclosed |
| US-8399465-B2 | Compounds with two fused bicyclic heteroaryl moieties as modulators of leukotriene A4 hydrolase | JANSSEN PHARMACEUTICA NV (BE) | 2013-03-19 | — | — | US | disclosed |
| US-8399465-B2 | Compounds with two fused bicyclic heteroaryl moieties as modulators of leukotriene A4 hydrolase | JANSSEN PHARMACEUTICA NV (BE) | 2013-03-19 | — | — | US | disclosed |
| EP-2536730-A1 | PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF CDK4/6 | Novartis AG (CH) | 2012-12-26 | — | — | EP | disclosed |
| WO-2011149874-A2 | N-PHENYL IMIDAZOLE CARBOXAMIDE INHIBITORS OF 3-PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE-1 | SCHERING CORPORATION (US) | 2011-12-01 | — | — | WO | disclosed |
| WO-2011101409-A1 | PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF CDK4/6 | NOVARTIS AG (CH) | 2011-08-25 | — | — | WO | disclosed |
| WO-2010132599-A1 | COMPOUNDS WITH TWO FUSED BICYCLIC HETEROARYL MOIETIES AS MODULATORS OF LEUKOTRIENE A4 HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2010-11-18 | — | — | WO | disclosed |
| US-20100292208-A1 | COMPOUNDS WITH TWO FUSED BICYCLIC HETEROARYL MOIETIES AS MODULATORS OF LEUKOTRIENE A4 HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2010-11-18 | — | — | US | disclosed |
| US-20100292208-A1 | COMPOUNDS WITH TWO FUSED BICYCLIC HETEROARYL MOIETIES AS MODULATORS OF LEUKOTRIENE A4 HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2010-11-18 | — | — | US | disclosed |
| EP-0746560-A1 | 3,8-DIAZABICYCLO 3.2.1]OCTANE DERIVATIVES HAVING ANALGESIC ACTIVITY | RIACE ESTABLISHMENT (LI) | 1996-12-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170112833-A1 | Tyrosine Kinase Inhibitor And Uses Thereof | EGFR, ERBB2, ABL1 | CHRNB2 4363/4885CHRNA3 4530/4885CHRNA4 4808/4885 |
| US-20100292208-A1 | COMPOUNDS WITH TWO FUSED BICYCLIC HETEROARYL MOIETIES AS MODULATORS OF LEUKOTRIENE A4 HYDROLASE | LTA4H, LTC4S, LTB4R | CHRNB2 2508/4885CHRNA3 2160/4885CHRNA4 924/4885 |
| US-10300058-B2 | Tyrosine kinase inhibitor and uses thereof | EGFR, ERBB2, ABL1 | CHRNB2 4363/4885CHRNA3 4530/4885CHRNA4 4808/4885 |
| US-20130150342-A1 | PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF CDK4/6 | CDK4, CDK6, CCNT1 | CHRNB2 4868/4885CHRNA3 4844/4885CHRNA4 4722/4885 |
| US-11230555-B2 | Bicyclic RORγ modulators | RORC, RORA, RORB | CHRNB2 793/4885CHRNA3 512/4885CHRNA4 654/4885 |
| US-20210053987-A1 | BICYCLIC ROR-GAMMA MODULATORS | RORA, RORC, RORB | CHRNB2 418/4885CHRNA3 280/4885CHRNA4 369/4885 |
| US-20220106329-A1 | BICYCLIC ROR-GAMMA MODULATORS | RORA, RORC, RORB | CHRNB2 418/4885CHRNA3 280/4885CHRNA4 369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.